Weight Loss Gold Rush: Legal and Regulatory Implications

Jim Shehan, Chair of Lowenstein Sandler’s FDA Regulatory Practice, discusses how the FDA and other regulators are likely to respond to growing public interest in GLP-1 drugs and their potential off-label uses, what GLP-1 would need to do to become regulated, and advice for investors and financiers considering entering the weight-loss drug market.